![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PIN1 |
Gene summary for PIN1 |
![]() |
Gene information | Species | Human | Gene symbol | PIN1 | Gene ID | 5300 |
Gene name | peptidylprolyl cis/trans isomerase, NIMA-interacting 1 | |
Gene Alias | DOD | |
Cytomap | 19p13.2 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q13526 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5300 | PIN1 | GSM4909291 | Human | Breast | IDC | 5.51e-08 | 3.86e-01 | 0.1753 |
5300 | PIN1 | GSM4909296 | Human | Breast | IDC | 2.77e-04 | 2.06e-01 | 0.1524 |
5300 | PIN1 | GSM4909297 | Human | Breast | IDC | 6.16e-08 | 2.86e-02 | 0.1517 |
5300 | PIN1 | GSM4909298 | Human | Breast | IDC | 1.16e-04 | 2.52e-01 | 0.1551 |
5300 | PIN1 | GSM4909301 | Human | Breast | IDC | 3.46e-02 | 2.54e-01 | 0.1577 |
5300 | PIN1 | GSM4909304 | Human | Breast | IDC | 1.57e-02 | 2.59e-01 | 0.1636 |
5300 | PIN1 | GSM4909308 | Human | Breast | IDC | 3.01e-24 | 5.25e-01 | 0.158 |
5300 | PIN1 | GSM4909311 | Human | Breast | IDC | 9.29e-17 | -7.79e-02 | 0.1534 |
5300 | PIN1 | GSM4909316 | Human | Breast | IDC | 2.73e-04 | 3.72e-01 | 0.21 |
5300 | PIN1 | GSM4909319 | Human | Breast | IDC | 5.25e-23 | 5.47e-02 | 0.1563 |
5300 | PIN1 | GSM4909320 | Human | Breast | IDC | 7.17e-03 | 1.20e-01 | 0.1575 |
5300 | PIN1 | GSM4909321 | Human | Breast | IDC | 7.44e-09 | 9.75e-02 | 0.1559 |
5300 | PIN1 | NCCBC5 | Human | Breast | DCIS | 9.36e-07 | 2.57e-01 | 0.2046 |
5300 | PIN1 | P1 | Human | Breast | IDC | 2.79e-02 | -1.64e-01 | 0.1527 |
5300 | PIN1 | DCIS2 | Human | Breast | DCIS | 9.03e-46 | 1.28e-01 | 0.0085 |
5300 | PIN1 | LZE4T | Human | Esophagus | ESCC | 2.73e-21 | 4.72e-01 | 0.0811 |
5300 | PIN1 | LZE5T | Human | Esophagus | ESCC | 1.24e-04 | 3.70e-01 | 0.0514 |
5300 | PIN1 | LZE7T | Human | Esophagus | ESCC | 1.44e-24 | 1.27e+00 | 0.0667 |
5300 | PIN1 | LZE8T | Human | Esophagus | ESCC | 1.11e-15 | 4.13e-01 | 0.067 |
5300 | PIN1 | LZE20T | Human | Esophagus | ESCC | 4.31e-08 | 3.26e-01 | 0.0662 |
Page: 1 2 3 4 5 6 7 8 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004352316 | Oral cavity | LP | regulation of neuron apoptotic process | 73/4623 | 212/18723 | 8.87e-04 | 7.64e-03 | 73 |
GO:004298211 | Oral cavity | LP | amyloid precursor protein metabolic process | 37/4623 | 95/18723 | 1.45e-03 | 1.14e-02 | 37 |
GO:006082815 | Oral cavity | LP | regulation of canonical Wnt signaling pathway | 82/4623 | 253/18723 | 3.23e-03 | 2.18e-02 | 82 |
GO:003011115 | Oral cavity | LP | regulation of Wnt signaling pathway | 103/4623 | 328/18723 | 3.29e-03 | 2.21e-02 | 103 |
GO:000679012 | Oral cavity | LP | sulfur compound metabolic process | 106/4623 | 339/18723 | 3.36e-03 | 2.25e-02 | 106 |
GO:190121515 | Oral cavity | LP | negative regulation of neuron death | 69/4623 | 208/18723 | 3.50e-03 | 2.34e-02 | 69 |
GO:000647016 | Oral cavity | LP | protein dephosphorylation | 89/4623 | 281/18723 | 4.60e-03 | 2.93e-02 | 89 |
GO:004828511 | Oral cavity | LP | organelle fission | 145/4623 | 488/18723 | 6.02e-03 | 3.57e-02 | 145 |
GO:009026315 | Oral cavity | LP | positive regulation of canonical Wnt signaling pathway | 38/4623 | 106/18723 | 6.67e-03 | 3.89e-02 | 38 |
GO:006007015 | Oral cavity | LP | canonical Wnt signaling pathway | 94/4623 | 303/18723 | 6.97e-03 | 3.96e-02 | 94 |
GO:00070881 | Oral cavity | LP | regulation of mitotic nuclear division | 39/4623 | 110/18723 | 7.45e-03 | 4.14e-02 | 39 |
GO:004298712 | Oral cavity | LP | amyloid precursor protein catabolic process | 26/4623 | 68/18723 | 9.08e-03 | 4.85e-02 | 26 |
GO:190165323 | Oral cavity | EOLP | cellular response to peptide | 85/2218 | 359/18723 | 2.06e-10 | 2.06e-08 | 85 |
GO:002241121 | Oral cavity | EOLP | cellular component disassembly | 94/2218 | 443/18723 | 1.00e-08 | 4.89e-07 | 94 |
GO:004343424 | Oral cavity | EOLP | response to peptide hormone | 89/2218 | 414/18723 | 1.29e-08 | 6.11e-07 | 89 |
GO:003530322 | Oral cavity | EOLP | regulation of dephosphorylation | 39/2218 | 128/18723 | 1.39e-08 | 6.43e-07 | 39 |
GO:003286922 | Oral cavity | EOLP | cellular response to insulin stimulus | 53/2218 | 203/18723 | 1.65e-08 | 7.43e-07 | 53 |
GO:007137523 | Oral cavity | EOLP | cellular response to peptide hormone stimulus | 68/2218 | 290/18723 | 1.98e-08 | 8.62e-07 | 68 |
GO:003286823 | Oral cavity | EOLP | response to insulin | 62/2218 | 264/18723 | 7.78e-08 | 2.76e-06 | 62 |
GO:003109923 | Oral cavity | EOLP | regeneration | 50/2218 | 198/18723 | 1.30e-07 | 4.25e-06 | 50 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa032509 | Esophagus | ESCC | Viral life cycle - HIV-1 | 54/4205 | 63/8465 | 2.01e-09 | 2.17e-08 | 1.11e-08 | 54 |
hsa0325014 | Esophagus | ESCC | Viral life cycle - HIV-1 | 54/4205 | 63/8465 | 2.01e-09 | 2.17e-08 | 1.11e-08 | 54 |
hsa032502 | Liver | HCC | Viral life cycle - HIV-1 | 46/4020 | 63/8465 | 3.25e-05 | 1.88e-04 | 1.04e-04 | 46 |
hsa0325011 | Liver | HCC | Viral life cycle - HIV-1 | 46/4020 | 63/8465 | 3.25e-05 | 1.88e-04 | 1.04e-04 | 46 |
hsa032508 | Oral cavity | OSCC | Viral life cycle - HIV-1 | 45/3704 | 63/8465 | 7.62e-06 | 3.59e-05 | 1.83e-05 | 45 |
hsa04622 | Oral cavity | OSCC | RIG-I-like receptor signaling pathway | 41/3704 | 71/8465 | 1.20e-02 | 2.63e-02 | 1.34e-02 | 41 |
hsa0325013 | Oral cavity | OSCC | Viral life cycle - HIV-1 | 45/3704 | 63/8465 | 7.62e-06 | 3.59e-05 | 1.83e-05 | 45 |
hsa046221 | Oral cavity | OSCC | RIG-I-like receptor signaling pathway | 41/3704 | 71/8465 | 1.20e-02 | 2.63e-02 | 1.34e-02 | 41 |
hsa0325022 | Oral cavity | LP | Viral life cycle - HIV-1 | 32/2418 | 63/8465 | 1.55e-04 | 9.08e-04 | 5.86e-04 | 32 |
hsa046222 | Oral cavity | LP | RIG-I-like receptor signaling pathway | 30/2418 | 71/8465 | 9.09e-03 | 3.33e-02 | 2.14e-02 | 30 |
hsa0325031 | Oral cavity | LP | Viral life cycle - HIV-1 | 32/2418 | 63/8465 | 1.55e-04 | 9.08e-04 | 5.86e-04 | 32 |
hsa046223 | Oral cavity | LP | RIG-I-like receptor signaling pathway | 30/2418 | 71/8465 | 9.09e-03 | 3.33e-02 | 2.14e-02 | 30 |
hsa032504 | Prostate | BPH | Viral life cycle - HIV-1 | 24/1718 | 63/8465 | 8.32e-04 | 3.98e-03 | 2.46e-03 | 24 |
hsa0325012 | Prostate | BPH | Viral life cycle - HIV-1 | 24/1718 | 63/8465 | 8.32e-04 | 3.98e-03 | 2.46e-03 | 24 |
hsa0325021 | Prostate | Tumor | Viral life cycle - HIV-1 | 25/1791 | 63/8465 | 6.13e-04 | 3.07e-03 | 1.91e-03 | 25 |
hsa032503 | Prostate | Tumor | Viral life cycle - HIV-1 | 25/1791 | 63/8465 | 6.13e-04 | 3.07e-03 | 1.91e-03 | 25 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PIN1 | SNV | Missense_Mutation | novel | c.256N>A | p.Leu86Met | p.L86M | Q13526 | protein_coding | tolerated(0.25) | benign(0.301) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PIN1 | SNV | Missense_Mutation | c.416T>C | p.Phe139Ser | p.F139S | Q13526 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-Q1-A5R2-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PR | |
PIN1 | SNV | Missense_Mutation | c.107N>C | p.Arg36Pro | p.R36P | Q13526 | protein_coding | tolerated(1) | benign(0.006) | TCGA-CA-6716-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | oxaliplatin | CR | |
PIN1 | SNV | Missense_Mutation | rs374933894 | c.314C>T | p.Ser105Phe | p.S105F | Q13526 | protein_coding | deleterious(0) | benign(0.439) | TCGA-D5-6930-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
PIN1 | SNV | Missense_Mutation | c.334N>A | p.Asp112Asn | p.D112N | Q13526 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PIN1 | SNV | Missense_Mutation | novel | c.166C>T | p.Arg56Cys | p.R56C | Q13526 | protein_coding | deleterious(0) | possibly_damaging(0.875) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PIN1 | SNV | Missense_Mutation | novel | c.409G>A | p.Ala137Thr | p.A137T | Q13526 | protein_coding | deleterious(0.01) | possibly_damaging(0.759) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
PIN1 | SNV | Missense_Mutation | novel | c.326A>G | p.Gln109Arg | p.Q109R | Q13526 | protein_coding | tolerated(0.24) | benign(0.003) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PIN1 | SNV | Missense_Mutation | novel | c.478N>A | p.Leu160Ile | p.L160I | Q13526 | protein_coding | tolerated(0.24) | probably_damaging(0.936) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
PIN1 | SNV | Missense_Mutation | c.115N>T | p.Gly39Cys | p.G39C | Q13526 | protein_coding | deleterious(0.01) | benign(0.393) | TCGA-G3-A25U-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5300 | PIN1 | ENZYME, KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME | PURPURIN | PURPURIN | ||
5300 | PIN1 | ENZYME, KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME | Avastin+/-Tarceva | |||
5300 | PIN1 | ENZYME, KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME | TETRADECYLTHIOACETIC ACID | TETRADECYLTHIOACETIC ACID | ||
5300 | PIN1 | ENZYME, KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME | AG-537 | CHEMBL67535 | ||
5300 | PIN1 | ENZYME, KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME | LOBARIC ACID | LOBARIC ACID | ||
5300 | PIN1 | ENZYME, KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME | oxaliplatin | OXALIPLATIN | ||
5300 | PIN1 | ENZYME, KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME | irinotecan | IRINOTECAN | ||
5300 | PIN1 | ENZYME, KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME | EMBELIN | EMBELIN | ||
5300 | PIN1 | ENZYME, KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME | SENNOSIDE B | SENNOSIDE B | ||
5300 | PIN1 | ENZYME, KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME | SJ000044511 | CHEMBL592124 |
Page: 1 2 3 |